Global Tissue Engineering Devices Market - DOC by umx12098

VIEWS: 2 PAGES: 2

Global Tissue Engineering Devices Market document sample

More Info
									Imperial College London, UCL and NPL have received £4.2m funding from the DTI.
The funding is part of a programme to harness the commercial potential of micro and
nanotechnology (MNT) in the UK. This initiative was announced on 30th March by
Lord Sainsbury, Science and Innovation Minister.

The project partners include the new Institute of Biomedical Engineering (IBE) at
Imperial College London, the London Centre for Nanotechnology (LCN), and the
National Physical Laboratory (NPL). The purpose of the project is to create facilities
in London to stimulate and service the growing bio-nanomedical industry in the UK
and to take global leadership in this emerging trillion dollar market. The investment
will enable industry to use state of the art nanotechnology in developing new bio-
medical products, such as diagnostic medical devices and drug delivery systems.

The project is supported and endorsed by several companies including large
multinationals and UK high-tech start-ups such as Millennium Chemicals, GSK,
Veeco, Sun Microsystems, GE Healthcare, Surface Technology Systems, Ionscope,
Toumaz Technology and Sphere Medical.

Bio-nanotechnology holds the key to future breakthroughs in medicine:
- It will deliver intelligent drug delivery systems
- Produce more accurate, less invasive biomedical imaging techniques for earlier
detection of diseases
- Create consumer healthcare products so an aging population is able to take better
care of itself
- Produce special bio-materials to restore or repair organs
- Design bio-electronic systems for restoring or augmenting body functions such as
sight, sound, and even mental functions

The project will involve the development of the following facilities:
- a rapid prototyping facility at the IBE for bio-nanomedical product development
- a computer-aided design facility at LCN for the virtual prototyping and simulation of
new bio-nano devices
- metrology and standards development for bio-nano devices at the NPL

In addition the London Development Authority is seed funding a Bio-Nanotechnology
Centre (BNC) product development organisation that will use these facilities to
service industry.

The project will enable start-ups and large companies to undertake high-risk high-
potential ventures in bio-nanotechnology, thereby creating high-tech jobs and
stimulating the innovation economy in the UK in this important global market.

£1.8 m of the total funding will be spent on the rapid prototyping facilities in the IBE to
extend its bio-nanotechnology laboratories and to complement its other state-of-the-
art labs in bionics, biomechanics, biomaterials and tissue engineering, and
biomedical imaging. These facilities are all meant for commercially-oriented research
that involves interdisciplinary and high-tech research resources that no single
industrial organisation can undertake on its own. The IBE is developing a diverse
community of companies to work with it. Collaborative research is also being
undertaken with other universities from the US to Singapore.
Prof Chris Toumazou
Executive Director- Institute of Biomedical Engineering
Imperial College

'I am delighted that the DTI has considered the Institute of Biomedical Engineering to
be a major resource for Bio-nanotechnolgy. This is a great opportunity for the IBE to
strengthen its core nano base in an environment where we are witnessing a new
wave in healthcare technologies."


Quote from Professor Tony Cass from the Institute of Biomedical Engineering

“The establishment of a major Bionanotechnology facility at Imperial College
recognises the strength of our expertise in this rapidly developing field. The
combination of a rapid prototyping micro and nano fabrication centre with the world-
class facilities of the Institute of Biomedical Engineering provides a unique
environment for engineers, scientists and clinicians to work together on realising the
promise of bionanotechnology in delivering improved healthcare.”


Contact Details

Omar Cheema
Business Development Director, Institute of Biomedical Engineering
T: 020.7594.6552
e: o.cheema@imperial.ac.uk


Further Information

         IBE, the Institute for Biomedical Engineering, is a £22 million interdisciplinary
institution of Imperial College London focussed on producing a range of innovative
and commercially-technology for the biomedical industry including the areas of bio-
nanotechnology, personalised healthcare, biomedical imaging, biomechanics, tissue
engineering and bio-materials


        LCN is among a handful of institutions at the forefront of the new bio-
nanotechnology field and is a joint venture between University College London and
Imperial College London. It. The LCN is unique in being the only nanotechnology
centre in the world to be situated in the heart of a metropolis, with ready access to
London’s world-leading medical research community

        NPL is the UK’s National Measurement Institute. It is ranked within the top
three of the world’s leading centres for metrology and standards. NPL represents a
£40 million pa government investment in metrology research, standards and
techniques to support UK industrial competitiveness, with a significant focus on the
micro and nano region. NPL has a specific Bio-metrology Research Programme,
applying the best practices in metrology to the biotechnology field.

								
To top